PTO/SB/30 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to

REQUEST **FOR**

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

a collection of information unless it of	displays a valid OMB control number.	_
Application Number	09/760,807	
Filing Date	January 17, 2001	1
Examiner Name	Loan H. Thanh	(
First Named Inventor	Maria Palasis	
Group Art Unit	3763	
Attorney Docket Number	1213/58101	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, NOTE: 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

a. Previously submitted i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered). ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on iii. Other b. Enclosed i. Amendment/Reply ii Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS) iv. Other: Submission of Formal Drawings
to above will be entered). ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on iii. Other b. Enclosed i. Amendment/Reply ii Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS)
ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on iii. Other b. Enclosed i. Amendment/Reply ii Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS)
iii.
i.
ii Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS)
iii. 🗵 Information Disclosure Statement (IDS)
2. Miscellaneous
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
b Other
3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.
 a. \int \text{ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. \frac{11-0600}{2}
i. RCE fee required under 37 C.F.R. § 1.17(e)
ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
iii. ☐ Other iv. ☑ Charge any additional fees under 37 C.F.R. § 1.16 and 1.17
b. Check in the amount of \$ enclosed
c. Payment by credit card (Form PTO-2038 enclosed)
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED
Name (Print /Type) Fred T Grasso. Registration No. (Attorney/Agent) 43,644
Signature Date May 16, 2006
CERTIFICATE OF MAILING OR TRANSMISSION/2006 JADDUL 00000078 110600 03
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:
Name (Print /Type)
Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.